FMR's passive 9.2% stake is a routine update with no change in investment stance. Monitor for any future conversion to Schedule 13D, which would signal activist intent, but no such indication exists in this filing.
PRAX drugs
PRAX drug pipeline →- ▲ relutrigine 8/10 Filed/PDUFA (NDA under priority review) · PDUFA date Dec 27, 2026
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027
- ● vormatrigine 5/10 Phase 3
- ◆ elsunersen 4/10 Phase 2/3 (registrational)
- ● PRAX-110 4/10
- 4 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $262.59entry
- T+1 · 11d ago +5.72%α +5.41% · $277.62
- T+5 · 5d ago +23.68%α +20.39% · $324.76
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 2,565,828 shares of Praxis Precision Medicines common stock as of September 30, 2026, representing 9.2% of outstanding shares. This is a routine passive stake update with no change in investment intent.
Key Financial Metrics
Key Facts
- FMR LLC reported beneficial ownership of 2,565,828 shares of Praxis Precision Medicines common stock as of September 30, 2026
- The stake represents 9.2% of outstanding shares
- Filing is an amendment to Schedule 13G, indicating passive investment intent
- FMR LLC subsidiaries FIAM LLC, Fidelity Management & Research Company LLC, and Strategic Advisers LLC are among the reporting entities
- Abigail P. Johnson is also reported as a beneficial owner of the same 2,565,828 shares (9.2%)
Financial Impact
2,565,828 shares valued at approximately $200M based on $7.8B market cap and 9.2% stake
Risk Factors
- No material risks identified from this routine passive stake filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000315066-26-002828 |
| Document: 0000315066-26-002828-index-headers.html | 0000315066-26-002828 |
| Document: 0000315066-26-002828-index.html | 0000315066-26-002828 |
| Document: 0000315066-26-002828.txt | 0000315066-26-002828 |
Track record
16 reports on PRAX
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Viewing Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers